 |
|
caracemide
An agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase. In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Chemical structure names: | | - acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI)
- N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea
| | |
|
|
